LOLena C. O'FLynn

Lena C. O'FLynn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lena C. O'FLynn has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perisynaptic matrix gene variants underlie DystoniaGeneNet endophenotypes in isolated focal dystonia

    by Aloysius Domingo, Dongren Yao, Nyah Kshatriya, Kotchaphorn Mangkalaphiban, Giovanni Battistella, Lena C. O’Flynn, Bailey Reese, Madison Hincher, Rachita Yadav, Nutan Sharma, et al.

    Isolated focal dystonia is a rare movement disorder characterized by abnormalities in brain structure and function. The genes underlying isolated focal dystonia are not fully elucidated, and genetic studies are constrained by incomplete penetrance and small family sizes. Neuroimaging endophenotypes shared by patients and unaffected relatives can reveal genetic liability independently of clinical manifestation and offer a strategy for advancing gene discovery. We developed DystoniaGeneNet, a 3D convolutional neural network that predicts familial status from T1-weighted brain MRIs. We then used its predictions to guide genetic analyses in isolated focal dystonia. DystoniaGeneNet was trained on 40 patients with familial laryngeal dystonia and 40 healthy controls, then applied to independent cohorts of 21 patients with familial isolated focal dystonia, 364 patients with sporadic dystonia, and 98 unaffected relatives. Model predictions were incorporated into variant prioritization and segregation analysis in 214 individuals with whole-exome sequencing data, and results were replicated in another 738 independent exomes, in genetic data from a hospital-based biobank (892 dystonia cases, 2,475 controls), and in the All of Us Research Program genetic data (1,343 dystonia cases, 6,840 controls). DystoniaGeneNet discriminated familial dystonia from healthy controls in the training set and correctly classified 85.7% of independent familial cases, using a biomarker centred on the corpus callosum and inferior temporal gyrus. Across the discovery and replication cohorts, we identified rare, likely pathogenic genetic variants in RAP1GAP and TNN segregating with disease in families. Additional variants were found in singletons with isolated focal dystonia. In patients with clinically sporadic dystonia but predicted to have familial features, we observed multiple rare variants in ITSN2 , including three high-confidence loss-of-function variants, and an enrichment of damaging missense variants in its Dbl homology domain. To determine the functional impact of discovered genetic variants, we assessed gene expression and splicing via qPCR and RNA sequencing ( n = 74), revealing reduced RAP1GAP and ITSN2 expression in variant carriers. At the pathway level, rare nonsynonymous variants in brain-expressed matrisome genes were associated with dystonia ( P = 0.012). Our strategy utilizing a deep learning-derived neuroimaging endophenotype to empower gene discovery uncovered RAP1GAP, TNN , and ITSN2 as novel genes associated with isolated focal dystonia. These genes converge on perisynaptic extracellular matrix-synapse signalling, implicating a mechanism linked to synaptic plasticity deficits, and identifying a molecular substrate for network-level brain abnormalities that characterize this disorder. Further, we exemplify a generalizable framework for leveraging endophenotypes in rare neurogenetic diseases with incomplete penetrance.

  • Open Access

    Breathe, Eat, Talk: Three Essential Ingredients to Quality‐of‐Life Outcomes in Movement Disorders

    by John Dean, Lena C. O’FLynn, Michelle Ciucci, Cynthia Fox, Jessica E. Huber, Supraja Anand, Maira Rozenfeld Olchik, Jibrin S. Usman, Adam P. Vogel, Bettina Aguiar, et al.

    Background: Breathing, eating, and talking (BET) impairments are common yet frequently underrecognized features of movement disorders. Deficits in respiration, swallowing, voice, and speech may emerge early in the course of a disease, adversely affecting safety, participation, and quality of life. Routine neurological examinations may not adequately capture their impact. Objective: To characterize the clinical importance of BET dysfunction across several movement disorders by comparing neurological and speech‐language pathology (SLP) approaches to assessment and recommendations for improved early identification, referral and multidisciplinary management. Methods: Case examples were used to illustrate and compare clinical findings obtained through standard neurological evaluation versus comprehensive SLP assessment. A targeted literature review and comparison of commonly used neurology and SLP clinical tools were also conducted to examine current approaches to BET evaluation and referral. Results: Case examples illustrated how routine neurological examinations underestimated the severity and functional impact of BET impairments. This was contrasted with SLP identification of clinically meaningful deficits in respiratory function, cough, swallowing safety, communication effectiveness, and quality of life not captured by standard disease rating scales. Review of the literature demonstrated that commonly used neurological rating scales provide limited evaluation of BET dysfunction, whereas multidisciplinary assessment incorporating caregiver input, patient‐reported outcomes, perceptual evaluation, and instrumental testing improves detection and treatment planning. Conclusion: BET dysfunction is prevalent across movement disorders and substantially influences quality of life. Early referral to SLPs and integration of multidisciplinary BET assessment can improve diagnostic precision, facilitate timely intervention, reduce preventable complications, and support person‐centered care throughout disease progression.

  • Long‐Term Daytime Use of Sodium Oxybate in Laryngeal Dystonia: A Follow‐Up Online Survey Study

    by Lena C. O'FLynn, Kristina Simonyan

    Background: Laryngeal dystonia (LD) is a task‐specific focal dystonia marked by involuntary spasms in the laryngeal muscles during speech production. Sodium oxybate has recently been demonstrated as a new treatment option for alcohol‐responsive (EtOH+) LD patients. Objective: The objective of this study is to evaluate the long‐term use of sodium oxybate for the treatment of LD. Methods: A total of 149 LD patients were invited to complete the online survey study. Seventy‐seven patients (mean age 65.2 ± 11.5 years, 54 females/23 males) completed 21 questions related to their disorder and the use of sodium oxybate. Results: Six patients (7.8%) reported receiving a prescription of sodium oxybate for the treatment of their voice symptoms. Of these, three EtOH+ patients (50%) reported receiving 1–1.25 g of sodium oxybate on an as‐needed basis, with an average of 79.3% ± 20.0% reduction in self‐perceived voice symptoms following drug intake. Drug usage ranged from three times per day 5 days per week to three times per month over the span of 6 months–12 years. Patients reported experiencing mild side effects that lasted 1–2 h, including drowsiness, dizziness, or nausea. The remaining three patients reported not being able to fill their prescriptions due to medical insurance reimbursements. Conclusions: Despite the limited sample size, this study demonstrates that the long‐term daytime use of sodium oxybate for the treatment of voice symptoms is safe and effective for EtOH+ isolated focal LD patients. The study highlights medical insurance coverage as one of the limiting factors hindering LD patients from accessing this medication. Level of Evidence: Level 4.


  • The Vodka Trial: Clinical and Genetic Characteristics of Alcohol Responsiveness in Laryngeal Dystonia

    by Lena C. O'Flynn, Aloysius Domingo, Azadeh Hamzehei Sichani, Ayumi Nishiyama, Madison Hincher, Rachita Yadav, Laurie J. Ozelius, Kristina Simonyan

    Background: Laryngeal dystonia (LD) is isolated task‐specific focal dystonia, predominantly impairing speech production. Clinical observations and population survey studies have reported that up to 58% of patients with LD may have symptom improvement following alcohol intake.Objectives: To determine the objective characteristics of alcohol responsiveness in LD using a standardized alcohol challenge test and genetic testing.Methods: A total of 109 patients with isolated focal LD participated in the study. Patients were administered two non‐diluted drinks of 40‐proof vodka 30 min apart, followed by assessments of voice symptoms, breath alcohol content, and side effects. Patients were considered alcohol‐responsive (EtOH+) if their symptoms changed by ≥10% from baseline. Whole‐exome sequencing was performed to identify genetic variants associated with the alcohol responsiveness of LD.Results: All patients tolerated the standardized alcohol challenge test without major adverse events. Fifty‐two patients (47.7%) had an average of 44.4 ± 25.0% improvement of LD symptoms about 45 min after alcohol intake. Five genetic variants in GABAergic pathway‐related genes were enriched in EtOH+ patients, and two of these, rs11644926 (ADCY7) and rs2230741 (ADCY9), were associated with the improvement of dystonic voice symptoms.Conclusions: Alcohol responsiveness of LD symptoms is a robust feature related to the genes regulating the GABAergic synapses. This finding provides support for the evaluation of novel oral medications with mechanisms of action similar to alcohol for the treatment of patients with alcohol‐responsive dystonia.